Australia's most trusted
source of pharma news
Thursday, 12 February 2026
Posted 3 July 2025 AM
AbbVie is dropping $3.19 billion to fortify its immunology portfolio with a next-gen in vivo CAR T treatment.
The deal sees AbbVie paying up to $3.19 billion ($2.1 billion) to acquire Capstan, which gives it the potential first-in-class lead asset CPTX2309, currently in a Phase 1 trial for the treatment of B cell-mediated autoimmune disorders, along with the targeted lipid nanoparticle (tLNP) delivery system.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.